---
title: FidoCure® Precision Medicine Data Showcased at the American Association of Cancer Research (AACR)
description: FidoCure Presents New Research at AACR 2023 Showcasing Power of Real-World Data from Dogs with Cancer feauring comparative oncology studies
image: https://blog.fidocure.com/hubfs/Imported_Blog_Media/shutterstock_124450252.jpg
---
[](https://www.fidocure.com/)
- [Veterinarians](https://fidocure.com/for-veterinarians/)
- [Portal Login](https://dvm.fidocure.com/)
- [Veterinary Blog](https://blog.fidocure.com/fidocure-blog/tag/vet)
- [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies)
- [Webinars](https://blog.fidocure.com/fidocure-blog/tag/webinars)
- [Pet Parents](https://fidocure.com/pet-parents/)
- [About Us](https://fidocure.com/about-us/)
- [How it works](https://fidocure.com/how-it-works/)
- [Find a Clinic](https://fidocure.com/find-a-clinic/)
- [Contact Us](https://fidocure.com/contact-us/)
# FidoCure® Precision Medicine Data Showcased at the American Association of Cancer Research (AACR)
[Dr. Lucas Rodrigues](https://blog.fidocure.com/fidocure-blog/author/dr-lucas-rodrigues)
[Share this blog post on Twitter](https://twitter.com/intent/tweet?text=I+found+this+interesting+blog+post&url=https://blog.fidocure.com/fidocure-blog/new-comparative-oncology-research-showcasing-power-of-real-world-data-from-dogs-with-cancer) [Share this blog post on Facebook](http://www.facebook.com/share.php?u=https://blog.fidocure.com/fidocure-blog/new-comparative-oncology-research-showcasing-power-of-real-world-data-from-dogs-with-cancer) [Share this blog post on LinkedIn](http://www.linkedin.com/shareArticle?mini=true&url=https://blog.fidocure.com/fidocure-blog/new-comparative-oncology-research-showcasing-power-of-real-world-data-from-dogs-with-cancer)
At the [AACR 2023 annual meeting](https://www.aacr.org/), Dr. Lucas Rodrigues, Head of Veterinary Research at FidoCure®, presented the results of two innovative studies which demonstrated the power of real-world data from dogs with cancer to drive drug development strategies and inform human clinical trials.
The first study, titled "High frequency of TP53 mutations in canine skin tumors recapitulates solar induced human lesions representing an important research model of spontaneous diseases," focused on the similarities between skin tumors in dogs and humans caused by sun exposure. The study found a high frequency of TP53 mutations in canine skin tumors, mirroring those seen in humans with solar-induced skin lesions. This validates the use of dogs as a valuable research model for spontaneous diseases.
[](https://blog.fidocure.com/hubfs/AACR_%20Targeting%20RAS%20-%20NRAS%20Canine%20HSA.pptx.png)
The second study, titled “Use of real-world data of dogs with cancer to drive drug development strategy and inform human clinical trials”, was very well received by the audience. This study highlighted the importance of data-driven decision making in drug development and clinical trial design. The research showed that leveraging real-world data of dogs with cancer can lead to faster and more cost-effective drug development strategies and more accurate clinical trial designs. This can greatly speed up the process of drug development and implementation.
[](https://blog.fidocure.com/hubfs/Use%20of%20real-world%20data%20of%20dogs%20with%20cancer%20to%20drive%20drug%20development%20strategy%20and%20inform%20human%20clinical%20trials.png)
As Dr. Lucas Rodrigues presented the results of these two groundbreaking studies at the AACR 2023 annual meeting, it became increasingly clear that FidoCure® is at the cutting edge of harnessing the power of real-world data to drive cancer research and drug development. In doing so, FidoCure® is paving the way for a new era of cancer research that is more patient-centric, with the aim of improving outcomes for both humans and our canine companions.
Our studies are opening the door to a new, powerful approach in developing cancer treatments and can help to bridge the gap between treating animals and humans.
## Related Articles
[](https://blog.fidocure.com/fidocure-blog/hemangiosarcoma-advancing-canine-cancer-treatment-with-targeted-therapies)
### [Hemangiosarcoma: Advancing canine cancer treatment with targeted therapies](https://blog.fidocure.com/fidocure-blog/hemangiosarcoma-advancing-canine-cancer-treatment-with-targeted-therapies)
Canine cancer diagnoses can be devastating and demoralizing. While research and studies for human cancer have brought us a long way when it comes to treatment and...
[FidoCure](https://blog.fidocure.com/fidocure-blog/author/fidocure)
[Read More](https://blog.fidocure.com/fidocure-blog/hemangiosarcoma-advancing-canine-cancer-treatment-with-targeted-therapies)
[](https://blog.fidocure.com/fidocure-blog/aacr5years)
[Vet](https://blog.fidocure.com/fidocure-blog/tag/vet)
### [Celebrating 5 Years of Research at AACR](https://blog.fidocure.com/fidocure-blog/aacr5years)
**FidoCure by the One Health Company and Stanford University Research Shared at AACR 2024 **
[Christina K. Lopes](https://blog.fidocure.com/fidocure-blog/author/christina-k-lopes)
[Read More](https://blog.fidocure.com/fidocure-blog/aacr5years)
- [How it Works](https://fidocure.com/how-it-works/)
- [FAQ](https://fidocure.com/faq/)
- [Contact Us](https://fidocurestg.wpengine.com/contact-us/)
- [For Vets](https://fidocure.com/for-veterinarians/)
- [About Us](https://fidocure.com/about-us/)
- [Terms of Service](https://fidocure.com/terms-of-service/)
- [Blog](https://blog.fidocure.com/fidocure-blog)
- [Careers](https://fidocure.com/careers/)
- [Privacy Policy](https://fidocure.com/privacy-policy/)
-
-
-
-
**FidoCure® is an advanced cancer-care service for dogs, developed by One Health Company**. DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.
© Copyright 2018-2026 One Health Company, All rights reserved
```json
{
"@context" : "https://schema.org",
"@type" : "BlogPosting",
"author" : {
"@type" : "Person",
"name" : "Dr. Lucas Rodrigues",
"url" : "https://blog.fidocure.com/fidocure-blog/author/dr-lucas-rodrigues"
},
"dateModified" : "2023-04-21T03:04:11.960Z",
"datePublished" : "2023-04-20T21:19:41.000Z",
"headline" : "FidoCure® Precision Medicine Data Showcased at the American Association of Cancer Research (AACR)",
"image" : [ "https://blog.fidocure.com/hubfs/Imported_Blog_Media/shutterstock_124450252.jpg" ],
"mainEntityOfPage" : {
"@id" : "https://blog.fidocure.com/fidocure-blog/new-comparative-oncology-research-showcasing-power-of-real-world-data-from-dogs-with-cancer",
"@type" : "WebPage"
},
"publisher" : {
"@type" : "Organization",
"logo" : {
"@type" : "ImageObject",
"url" : "https://blog.fidocure.com/hubfs/fidocure_logo.png"
},
"name" : "FidoCure"
}
}
```